Drug Target Review: The Potential of CD24 in Cancer Immunotherapy

January 5, 2024

In this Q&A with Drug Target Review, our cofounder and CSO, Dr. Roy Maute revewals Pheast’s promising drug candidate and explains why they have focused on their chosen target. Dr. Maute says, “By blocking CD24 with an antibody drug, our goal is to powerfully reactivate the anti-cancer immune response and drive therapeutic efficacy.”

Read the full article online here.